Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Japan
  4. Japan Exchange
  5. Daiichi Sankyo Company, Limited
  6. Summary
    4568   JP3475350009

DAIICHI SANKYO COMPANY, LIMITED

(4568)
  Report
 SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Japan Exchange
10/11/2021 10/12/2021 10/13/2021 10/14/2021 10/15/2021 Date
2951.5 2930.5 2900 2920 2942.5 Last
4429100 2750800 2213800 2916200 2581800 Volume
+1.76% -0.71% -1.04% +0.69% +0.77% Change
Estimated financial data (e)
Sales 2022 1 003 B 8 775 M 8 775 M
Net income 2022 58 792 M 515 M 515 M
Net cash position 2022 624 B 5 465 M 5 465 M
P/E ratio 2022 96,6x
Yield 2022 0,91%
Sales 2023 1 058 B 9 259 M 9 259 M
Net income 2023 79 793 M 698 M 698 M
Net cash position 2023 665 B 5 817 M 5 817 M
P/E ratio 2023 71,1x
Yield 2023 0,97%
Capitalization 5 640 B 49 400 M 49 361 M
EV / Sales 2022 5,00x
EV / Sales 2023 4,70x
Nbr of Employees 16 033
Free-Float 97,6%
More Financials
Company
Daiichi Sankyo Co Ltd is a Japan-based company mainly engaged in the manufacture and sale of pharmaceuticals. The Company is involved in the research, development, manufacture and sale of pharmaceuticals, as well as the provision of intermediates and basic materials for pharmaceutical producing in Japan, the United States, Europe and other markets. The Company is also engaged in the research, development,... 
Sector
Pharmaceuticals
Calendar
10/29Earnings Release
More about the company
Ratings of Daiichi Sankyo Company, Limited
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B
More Ratings
All news about DAIICHI SANKYO COMPANY, LIMITED
10/13PRESS RELEASE : Defence Therapeutics Inc.: DEFENCE THERAPEUTICS ACCUMTM VARIANTS IN VITRO ..
DJ
10/11DAIICHI SANKYO : Corporate Governance Report
PU
10/05DAIICHI SANKYO : Astrazeneca - Enhertu granted Breakthrough Therapy Designation in US for ..
AQ
10/04Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) and AstraZeneca Receive Gra..
CI
10/04ASTRAZENECA : Daiichi Sankyo's Enhertu Gets US FDA Breakthrough Therapy Tag for Breast Can..
MT
10/04AstraZeneca Says FDA Granted Breakthrough-Therapy Designation for Cancer Treatment Enhe..
DJ
09/29DAIICHI SANKYO COMPANY, LIMITED : Ex-dividend day for interim dividend
FA
09/21Nikkei 225 Falls 2.2% on China Property Outlook
MT
09/20Japanese shares fall on Evergrande jitters; bargain-hunting limits losses
RE
09/20DAIICHI SANKYO : Enhertu reduced the risk of disease progression or death by 72% vs. trast..
AQ
09/20DAIICHI SANKYO : Enhertu demonstrated robust and durable tumour response of 54.9% in patie..
AQ
09/20ASTRAZENECA : Touts Positive Survival Data for Cancer Therapies Imfinzi, Enhertu
MT
09/20DAIICHI SANKYO : Enhertu demonstrated clinically meaningful and durable response in patien..
AQ
09/20ASTRAZENECA : Daiichi Sankyo's Enhertu Reduces Breast Cancer Death In Late-Stage Study
MT
09/20ASTRAZENECA : Daiichi Sankyo's Enhertu Shows 55% Tumor Response Rate in Lung Cancer Patien..
MT
More news
News in other languages on DAIICHI SANKYO COMPANY, LIMITED
10/13DEFENCE THERAPEUTICS INC. : Bei einer In Vitro-Studie erhöhen eie Accumtm-Varianten von De..
10/13Bei einer in vitro-studie erhöhen die accum(tm)-varianten von defence therapeutics die ..
10/04ASTRAZENECA : statut de 'breakthrough therapy' pour Enhertu
10/04FDA gibt Astrazeneca-Krebsmittel Enhertu Status als Durchbruchtherapie
10/04Le médicament Enhertu d'AstraZeneca-Daiichi Sankyo reçoit le label Breakthrough Therapy..
More news
Analyst Recommendations on DAIICHI SANKYO COMPANY, LIMITED
More recommendations
Chart DAIICHI SANKYO COMPANY, LIMITED
Duration : Period :
Daiichi Sankyo Company, Limited Technical Analysis Chart | 4568 | JP3475350009 | MarketScreener
Technical analysis trends DAIICHI SANKYO COMPANY, LIMITED
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 13
Last Close Price 2 942,50 JPY
Average target price 3 753,85 JPY
Spread / Average Target 27,6%
EPS Revisions
Managers and Directors
Sunao Manabe President, CEO & Representative Director
Hiroyuki Okuzawa CFO, Director, Executive Officer & Head-Management
Ken Takeshita Global Director-Research & Development
Noritaka Uji Independent Outside Director
Tsuguya Fukui Independent Outside Director
Sector and Competitors
1st jan.Capi. (M$)
DAIICHI SANKYO COMPANY, LIMITED-16.76%49 400
JOHNSON & JOHNSON2.49%424 619
ROCHE HOLDING AG16.59%339 442
NOVO NORDISK A/S54.22%234 792
PFIZER, INC.13.20%232 621
ELI LILLY AND COMPANY40.89%215 657